Archive: Diversity

SubjectWell recently fielded a survey engaging over 300 type 2 diabetes patients. The findings showed that diabetes patients demonstrated high overall interest in clinical trial participation, but secondary conditions caused by their diabetes can shift that interest higher or lower. According to the CDC, more than 33 million Americans have type 2 diabetes. As patients’

Minority populations are significantly underrepresented in clinical research. When comparing the FDA’s recent Drug Trial Snapshots data with US Census data, women, white patients, and older patients are shown to be overrepresented in clinical trials. Black patients make up just 8% and Hispanic patients 11% of trial participants — much lower than their general population

For a clinical trial to be successful, patients need to be the top priority. However, language barriers faced during the clinical trial process can often result in lower participation rates of non-English speakers, an unsatisfactory patient experience and, ultimately, imprecise data. In the US, the leading country in clinical trial participation each year, language barriers

Since the start of the pandemic, SubjectWell has kept a close eye on patient attitudes and feelings toward clinical trials. After all, right now is arguably the most critical time for clinical trial participation as COVID-19 cases continue to rise worldwide and vaccines and treatments are still being tested. By understanding what prevents or encourages

Enrolling a diverse pool of patients is often a challenge for sponsors and CROs. Fortunately, digital patient outreach can help boost clinical trial recruitment efforts.

Although real world evidence (RWE) is gaining steam in the healthcare industry, it doesn’t pose a threat to traditional clinical trials. Here’s what sponsors and CRO’s need to know:

In order to determine the safety and efficacy of new treatments, it’s crucial for clinical trials to recruit racially and ethnically diverse patients.

In a recent study, 73% of people who had not participated in a clinical trial reported they would be open to doing so. Now it’s up to sponsors and CROs to engage this untapped audience.

African-Americans are underrepresented in many clinical trials. Here are three steps CROs and sponsors can take to improve recruitment of minority patients.

Starting this fall, Facebook will no longer allow advertisers to target based on racial and ethnic identifiers. Here’s what that means for clinical trials looking to recruit a racially diverse group of patients.